SELLAS Life Sciences Group, Inc. Mon, October 17, 2022 at 2:30 Pm
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Group, Inc. NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host an update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) on November 14, 2022.
The call will be facilitated by SELLAS management, including SELLAS’ President and CEO, Angelos Stergiou, MD, ScD h.c., and Senior Vice President, Clinical Development, Dragan Cicic, MD, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee. Further details regarding how to access the update call will be provided in the coming weeks
bigbaeng,lass dich nicht entmutigen von deinem flopp bei der valneva,hier gibt es noch guenstige tickets,in 3 wochen werden die weichen gestellt sein,,,,,....
SELLAS Life Sciences Group, Inc. (SLS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Add to watchlist Quote Lookup
2.3775-0.0225 (-0.94%) As of 09:49AM EDT. Market open.
|